The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

Neuroblastoma (NB) is the most common solid tumor of the neural crest cell origin in children and has a poor prognosis in high-risk patients. The oncogene MYCN was found to be amplified at extremely high levels in approximately 20% of neuroblastoma cases. In recent years, research on the targeted hy...

Full description

Saved in:
Bibliographic Details
Main Authors: Si-Qi Jia, Ran Zhuo, Zi-Mu Zhang, Yang Yang, Yan-Fang Tao, Jian-Wei Wang, Xiao-Lu Li, Yi Xie, Gen Li, Di Wu, Yan-Ling Chen, Juan-Juan Yu, Chen-xi Feng, Zhi-Heng Li, Rong-Fang Zhou, Ran-Dong Yang, Peng-Cheng Yang, Bi Zhou, Xiao-Mei Wan, Yu-Meng Wu, Wan-Yan Jiao, Ni-Na Zhou, Fang Fang, Jian Pan
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2022/7945884
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849435062321283072
author Si-Qi Jia
Ran Zhuo
Zi-Mu Zhang
Yang Yang
Yan-Fang Tao
Jian-Wei Wang
Xiao-Lu Li
Yi Xie
Gen Li
Di Wu
Yan-Ling Chen
Juan-Juan Yu
Chen-xi Feng
Zhi-Heng Li
Rong-Fang Zhou
Ran-Dong Yang
Peng-Cheng Yang
Bi Zhou
Xiao-Mei Wan
Yu-Meng Wu
Wan-Yan Jiao
Ni-Na Zhou
Fang Fang
Jian Pan
author_facet Si-Qi Jia
Ran Zhuo
Zi-Mu Zhang
Yang Yang
Yan-Fang Tao
Jian-Wei Wang
Xiao-Lu Li
Yi Xie
Gen Li
Di Wu
Yan-Ling Chen
Juan-Juan Yu
Chen-xi Feng
Zhi-Heng Li
Rong-Fang Zhou
Ran-Dong Yang
Peng-Cheng Yang
Bi Zhou
Xiao-Mei Wan
Yu-Meng Wu
Wan-Yan Jiao
Ni-Na Zhou
Fang Fang
Jian Pan
author_sort Si-Qi Jia
collection DOAJ
description Neuroblastoma (NB) is the most common solid tumor of the neural crest cell origin in children and has a poor prognosis in high-risk patients. The oncogene MYCN was found to be amplified at extremely high levels in approximately 20% of neuroblastoma cases. In recent years, research on the targeted hydrolysis of BRD4 to indirectly inhibit the transcription of the MYCN created by proteolysis targeting chimaera (PROTAC) technology has become very popular. dBET57 (S0137, Selleck, TX, USA) is a novel and potent heterobifunctional small molecule degrader based on PROTAC technology. The purpose of this study was to investigate the therapeutic effect of dBET57 in NB and its potential mechanism. In this study, we found that dBET57 can target BRD4 ubiquitination and disrupt the proliferation ability of NB cells. At the same time, dBET57 can also induce apoptosis, cell cycle arrest, and decrease migration. Furthermore, dBET57 also has a strong antiproliferation function in xenograft tumor models in vivo. In terms of mechanism, dBET57 targets the BET protein family and the MYCN protein family by associating with CRBN and destroys the SE landscape of NB cells. Combined with RNA-seq and ChIP-seq public database analysis, we identified the superenhancer-related genes TBX3 and ZMYND8 in NB as potential downstream targets of dBET57 and experimentally verified that they play an important role in the occurrence and development of NB. In conclusion, these results suggest that dBET57 may be an effective new therapeutic drug for the treatment of NB.
format Article
id doaj-art-e42b467cdd344ef6a7ec6c79f6e4847d
institution Kabale University
issn 2314-7156
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-e42b467cdd344ef6a7ec6c79f6e4847d2025-08-20T03:26:25ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/7945884The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in NeuroblastomaSi-Qi Jia0Ran Zhuo1Zi-Mu Zhang2Yang Yang3Yan-Fang Tao4Jian-Wei Wang5Xiao-Lu Li6Yi Xie7Gen Li8Di Wu9Yan-Ling Chen10Juan-Juan Yu11Chen-xi Feng12Zhi-Heng Li13Rong-Fang Zhou14Ran-Dong Yang15Peng-Cheng Yang16Bi Zhou17Xiao-Mei Wan18Yu-Meng Wu19Wan-Yan Jiao20Ni-Na Zhou21Fang Fang22Jian Pan23Institute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchInstitute of Pediatric ResearchNeuroblastoma (NB) is the most common solid tumor of the neural crest cell origin in children and has a poor prognosis in high-risk patients. The oncogene MYCN was found to be amplified at extremely high levels in approximately 20% of neuroblastoma cases. In recent years, research on the targeted hydrolysis of BRD4 to indirectly inhibit the transcription of the MYCN created by proteolysis targeting chimaera (PROTAC) technology has become very popular. dBET57 (S0137, Selleck, TX, USA) is a novel and potent heterobifunctional small molecule degrader based on PROTAC technology. The purpose of this study was to investigate the therapeutic effect of dBET57 in NB and its potential mechanism. In this study, we found that dBET57 can target BRD4 ubiquitination and disrupt the proliferation ability of NB cells. At the same time, dBET57 can also induce apoptosis, cell cycle arrest, and decrease migration. Furthermore, dBET57 also has a strong antiproliferation function in xenograft tumor models in vivo. In terms of mechanism, dBET57 targets the BET protein family and the MYCN protein family by associating with CRBN and destroys the SE landscape of NB cells. Combined with RNA-seq and ChIP-seq public database analysis, we identified the superenhancer-related genes TBX3 and ZMYND8 in NB as potential downstream targets of dBET57 and experimentally verified that they play an important role in the occurrence and development of NB. In conclusion, these results suggest that dBET57 may be an effective new therapeutic drug for the treatment of NB.http://dx.doi.org/10.1155/2022/7945884
spellingShingle Si-Qi Jia
Ran Zhuo
Zi-Mu Zhang
Yang Yang
Yan-Fang Tao
Jian-Wei Wang
Xiao-Lu Li
Yi Xie
Gen Li
Di Wu
Yan-Ling Chen
Juan-Juan Yu
Chen-xi Feng
Zhi-Heng Li
Rong-Fang Zhou
Ran-Dong Yang
Peng-Cheng Yang
Bi Zhou
Xiao-Mei Wan
Yu-Meng Wu
Wan-Yan Jiao
Ni-Na Zhou
Fang Fang
Jian Pan
The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
Journal of Immunology Research
title The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
title_full The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
title_fullStr The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
title_full_unstemmed The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
title_short The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
title_sort brd4 inhibitor dbet57 exerts anticancer effects by targeting superenhancer related genes in neuroblastoma
url http://dx.doi.org/10.1155/2022/7945884
work_keys_str_mv AT siqijia thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT ranzhuo thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT zimuzhang thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT yangyang thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT yanfangtao thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT jianweiwang thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT xiaoluli thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT yixie thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT genli thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT diwu thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT yanlingchen thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT juanjuanyu thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT chenxifeng thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT zhihengli thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT rongfangzhou thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT randongyang thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT pengchengyang thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT bizhou thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT xiaomeiwan thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT yumengwu thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT wanyanjiao thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT ninazhou thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT fangfang thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT jianpan thebrd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT siqijia brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT ranzhuo brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT zimuzhang brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT yangyang brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT yanfangtao brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT jianweiwang brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT xiaoluli brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT yixie brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT genli brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT diwu brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT yanlingchen brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT juanjuanyu brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT chenxifeng brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT zhihengli brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT rongfangzhou brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT randongyang brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT pengchengyang brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT bizhou brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT xiaomeiwan brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT yumengwu brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT wanyanjiao brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT ninazhou brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT fangfang brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma
AT jianpan brd4inhibitordbet57exertsanticancereffectsbytargetingsuperenhancerrelatedgenesinneuroblastoma